Mersana Therapeutics (MRSN) Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ACCV
2. SPY
3. QQQ
4. AZN
5. SMMT
6. GMAB
7. IVBIY
8. IIB:IN
9. FICO
10. DRRD:IN

Go back to Mersana Therapeutics (MRSN) Provides Business Update

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

January 6, 2023 7:00 AM EST

Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in platinum-sensitive ovarian cancerAdvance XMT-1660 and XMT-2056 Phase 1 trials Continue pursuing collaborations to maximize platform and pipeline potentialCapital resources expected to support operating plan commitments into the second half of 2024

CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering... More